Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tbingen, Germany.

Immatics N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HOUSTON , TEXAS AND TUEBINGEN, GERMANY, DECEMBER 11, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AND THE GLOBAL LEADER IN PRECISION TARGETING OF PRAME, TODAY ANNOUNCED UPDATED PHASE 1A DOSE ESCALATION DATA FROM ITS SECOND-GENERATION PRAME CELL THERAPY, IMA203CD8, IN HEAVILY PRE-TREATED PATIENTS WITH SOLID TUMORS. BASED ON THE ENHANCED PHARMACOLOGY OF IMA203CD8 REPORTED PREVIOUSLY, IMA203CD8 PROVIDES THE POTENTIAL TO ADDRESS DIFFICULT-TO-TREAT SOLID TUMORS EXPRESSING PRAME BEYOND MELANOMA, SUCH AS OVARIAN CANCER.

IMMATICS PRESENTS IMA203CD8 PRAME CELL THERAPY DATA FROM ONGOING DOSE ESCALATION AND SHOWS PROMISING INITIAL ANTI-TUMOR ACTIVITY IN PRAME-POSITIVE TUMORS AT ESMO-IO 2025 CONGRESS

HOUSTON, TEXAS AND TUEBINGEN, GERMANY, DECEMBER 05, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AND THE GLOBAL LEADER IN PRECISION TARGETING OF PRAME, ANNOUNCED TODAY THAT IT HAS AGREED TO SELL 12,500,000 ORDINARY SHARES AT $10.00 PER SHARE IN AN UNDERWRITTEN OFFERING. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNT AND OFFERING EXPENSES, ARE EXPECTED TO BE $125 MILLION. THE OFFERING IS EXPECTED TO CLOSE ON DECEMBER 8, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

IMMATICS ANNOUNCES $125 MILLION UNDERWRITTEN OFFERING

ANZU-CEL (ANZUTRESGENE AUTOLEUCEL, IMA203) PRAME CELL THERAPY: GLOBAL, RANDOMIZED, CONTROLLED PHASE 3 TRIAL, SUPRAME, IN PREVIOUSLY TREATED ADVANCED MELANOMA ONGOING; INTERIM AND FINAL ANALYSES WILL OCCUR IN 2026 ANZU-CEL (IMA203) PRAME CELL THERAPY: ONE-TIME INFUSION CONTINUES TO SHOW STRONG CLINICAL BENEFIT AND FAVORABLE TOLERABILITY IN 16 PATIENTS WITH METASTATIC UVEAL MELANOMA IN LATEST UPDATE ON PHASE 1B DATA PRESENTED AT THE ESMO 2025 PRESIDENTIAL SYMPOSIUM: CORR OF 67%, MDOR OF 11.

IMMATICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 12, AT 8:30 AM EST/2:30 PM CET

IMMATICS ACHIEVES CLINICAL PROOF-OF-CONCEPT OF ITS NEXT-GENERATION TCR BISPECIFIC (TCER) PIPELINE WITH DATA ON IMA402 (PRAME) AND IMA401 (MAGEA4/8) AND ANNOUNCES NEXT DEVELOPMENT STEPS

HOUSTON , TEXAS AND TUEBINGEN, GERMANY, OCTOBER 27, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AND THE GLOBAL LEADER IN PRECISION TARGETING OF PRAME, TODAY ANNOUNCED THE APPOINTMENT OF AMIE KRAUSE AS CHIEF PEOPLE OFFICER (CPO) EFFECTIVE OCTOBER 27, 2025. MS. KRAUSE BRINGS MORE THAN 20 YEARS OF EXPERIENCE IN SHAPING CULTURE, LEADING ORGANIZATIONAL GROWTH AND ALIGNING TALENT WITH BUSINESS STRATEGY, INCLUDING ACROSS GLOBAL BIOPHARMACEUTICAL COMPANIES. IN THIS NEWLY ESTABLISHED ROLE, SHE WILL LEAD IMMATICS' HUMAN RESOURCES, FOCUSING ON ORGANIZATIONAL DEVELOPMENT AND OPERATIONS AS THE COMPANY TRANSITIONS TO COMMERCIAL STAGE. AS WE ENTER OUR NEXT PHASE OF TRANSFORMING INTO A COMMERCIAL-STAGE ENTERPRISE, WE ARE DELIGHTED TO WELCOME AMIE. HER EXPERIENCE IN BUILDING HIGH-PERFORMING TEAMS AS WELL AS ENHANCING ORGANIZATIONAL EXCELLENCE AND EFFICIENCY WILL HELP POSITION US FOR CONTINUED SUCCESS AS WE STRENGTHEN OUR GLOBAL LEADERSHIP IN PRECISION TARGETING OF PRAME, SAID HARPREET SINGH, PH.D., CHIEF EXECUTIVE OFFICER AND CO-FOUNDER OF IMMATICS. AMIE IS AN ACCOMPLISHED LEADER IN ALIGNING PEOPLE STRATEGY WITH BUSINESS OUTCOMES AND WILL BE A CRITICAL ADDITION TO THE LEADERSHIP TEAM AS WE ADVANCE OUR PIPELINE OF PRAME PRODUCT CANDIDATES AND PREPARE FOR THE COMMERCIALIZATION OF OUR LEAD PRAME CELL THERAPY CANDIDATE, ANZU-CEL, WITH THE GOAL OF PROVIDING BETTER OPTIONS TO PATIENTS WITH CANCER. IMMATICS IS AT A CRUCIAL STAGE IN ITS JOURNEY TO DELIVER INNOVATIVE THERAPIES TO PATIENTS WITH CANCER. I AM HONORED TO BE JOINING AT SUCH A TRANSFORMATIVE TIME AND WORKING ALONGSIDE A TALENTED TEAM, ADDED AMIE KRAUSE, CHIEF PEOPLE OFFICER OF IMMATICS. BUILDING ON IMMATICS' STRATEGIC VISION AND DIVERSE TALENT, I LOOK FORWARD TO FOSTERING A CULTURE THAT DRIVES ORGANIZATIONAL EXCELLENCE AND ENSURES WE ARE READY TO DELIVER ON THE PROMISE OF OUR PRAME FRANCHISE. AMIE KRAUSE JOINS IMMATICS FROM DOMP, WHERE SHE SERVED AS CHIEF HUMAN RESOURCES 

IMMATICS APPOINTS AMIE KRAUSE AS CHIEF PEOPLE OFFICER

HOUSTON , TEXAS AND TUEBINGEN, GERMANY, OCTOBER 20, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AND THE GLOBAL LEADER IN PRECISION TARGETING OF PRAME, TODAY ANNOUNCED THE PRESENTATION OF UPDATED DATA FROM 16 PATIENTS WITH METASTATIC UVEAL MELANOMA TREATED WITH ANZU-CEL PRAME CELL THERAPY.

IMMATICS HIGHLIGHTS COMPELLING ANTI-TUMOR ACTIVITY OF ANZU-CEL PRAME CELL THERAPY IN METASTATIC UVEAL MELANOMA AT THE ESMO 2025 PRESIDENTIAL SYMPOSIUM

HOUSTON, TEXAS AND TUEBINGEN, GERMANY, AUGUST 13, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AND THE GLOBAL LEADER IN PRECISION TARGETING OF PRAME, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

IMMATICS ANNOUNCES SECOND QUARTER 2025FINANCIAL RESULTS AND BUSINESS UPDATE

STAFFORD , TEXAS AND TUEBINGEN, GERMANY, MAY 31, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ACTIVE IN THE DISCOVERY AND DEVELOPMENT OF T CELL-REDIRECTING CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THE PRESENTATION OF EXPANDED DATA FROM THE ONGOING PHASE 1B CLINICAL TRIAL EVALUATING IMA203 PRAME CELL THERAPY IN HEAVILY PRETREATED PATIENTS WITH METASTATIC MELANOMA. THE LONGER FOLLOW-UP OF PATIENTS DEMONSTRATES A CONSISTENT AND FAVORABLE TOLERABILITY PROFILE AS WELL AS DURABLE RESPONSES WITH A CONFIRMED ORR OF 56%. IN ADDITION, THE COMPANY PROVIDED DETAILS FROM A TRIAL IN PROGRESS POSTER ON SUPRAME, THE ONGOING PHASE 3 CLINICAL TRIAL EVALUATING IMA203 IN PATIENTS WITH UNRESECTABLE OR METASTATIC CUTANEOUS MELANOMA WHO HAVE RECEIVED PRIOR TREATMENT WITH A CHECKPOINT INHIBITOR.

IMMATICS IMA203 PRAME CELL THERAPY DATA PRESENTED AT 2025 ASCO ANNUAL MEETING CONTINUES TO SHOW STRONG ANTI-TUMOR ACTIVITY AND DURABILITY IN PATIENTS WITH METASTATIC MELANOMA

HOUSTON, TEXAS AND TUEBINGEN, GERMANY, MAY 13, 2025  IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ACTIVE IN THE DISCOVERY AND DEVELOPMENT OF T CELL-REDIRECTING CANCER IMMUNOTHERAPIES, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025.

IMMATICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

HOUSTON, TEXAS AND TUEBINGEN, GERMANY, APRIL 23, 2025 IMMATICS N.V. (NASDAQ: IMTX, IMMATICS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ACTIVE IN THE DISCOVERY AND DEVELOPMENT OF T CELL-REDIRECTING CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED UPCOMING PRESENTATIONS ON ITS LEAD CELL THERAPY PRODUCT CANDIDATE, IMA203 TCR T-CELL THERAPY TARGETING PRAME, AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TO BE HELD FROM MAY 30  JUNE 3, 2025, IN CHICAGO, ILLINOIS.

Immatics N.V.

IMTX

Price

Financial Reports

No items found.

Press Releases

Immatics N.V.

IMTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMTX